Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

Similar articles for PubMed (Select 23954923)

1.

High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.

Iannone F, Gremese E, Gallo G, Sarzi-Puttini P, Botsios C, Trotta F, Gasperini S, Galeazzi M, Adami S, Cantini F, Sebastiani M, Gorla R, Marchesoni A, Giardina A, Foti R, Mele A, Bruschi E, Bagnato G, Erre GL, Lapadula G; GISEA (Gruppo Italiano Studio Early Arthritis).

Clin Rheumatol. 2014 Jan;33(1):31-7. doi: 10.1007/s10067-013-2348-6. Epub 2013 Aug 18.

PMID:
23954923
2.

Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.

Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R.

Clin Rheumatol. 2013 Sep;32(9):1275-81. doi: 10.1007/s10067-013-2240-4. Epub 2013 May 11.

PMID:
23666316
3.

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, Favalli EG, Erre GL, Gorla R, Galeazzi M, Foti R, Cantini F, Salvarani C, Olivieri I, Lapadula G, Ferraccioli G; Gruppo Italiano di Studio sulle Early Arthritis (GISEA).

Arthritis Care Res (Hoboken). 2013 Jan;65(1):94-100. doi: 10.1002/acr.21768.

PMID:
22730143
4.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B.

Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17.

PMID:
23332236
5.

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group.

J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. Erratum in: J Rheumatol. 2007 Sep;34(9):1947.

PMID:
17611987
6.

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.

Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G; Gruppo Italiano di Studio sulle Early Arthritides (GISEA).

J Rheumatol. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1.

PMID:
22467933
7.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

8.

Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.

Keystone E, Freundlich B, Schiff M, Li J, Hooper M.

J Rheumatol. 2009 Mar;36(3):522-31. doi: 10.3899/jrheum.080663. Epub 2009 Feb 17.

PMID:
19228659
9.

Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM.

Drugs Aging. 2006;23(2):167-78.

PMID:
16536638
10.

Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.

Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E.

Rheumatology (Oxford). 2014 Nov;53(11):1984-93. doi: 10.1093/rheumatology/keu235. Epub 2014 Jun 6.

PMID:
24907147
11.

Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.

Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, Takeuchi T.

Mod Rheumatol. 2012 Apr;22(2):186-94. doi: 10.1007/s10165-011-0510-z. Epub 2011 Sep 8.

PMID:
21901357
12.

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark.

Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.

13.

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B.

Lancet. 2008 Aug 2;372(9636):375-82. doi: 10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.

PMID:
18635256
14.

Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.

Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K.

Mod Rheumatol. 2009;19(5):488-92. doi: 10.1007/s10165-009-0187-8. Epub 2009 Jul 4.

PMID:
19578932
15.
16.

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.

Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52.

PMID:
20074482
17.

Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.

Wakabayashi H, Hasegawa M, Nishioka Y, Minami Y, Nishioka K, Sudo A.

Clin Rheumatol. 2013 Feb;32(2):253-9. doi: 10.1007/s10067-012-2118-x. Epub 2012 Nov 21.

PMID:
23179002
18.

Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.

Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS.

Ann Rheum Dis. 2012 Jun;71(6):989-92. doi: 10.1136/annrheumdis-2011-201066. Epub 2012 Mar 8.

PMID:
22402142
19.

[Indications for and use of biologics in early rheumatoid arthritis based on the evidence].

Takeuchi T.

Nihon Rinsho. 2009 May;67(5):1043-9. Review. Japanese.

PMID:
19432131
20.

Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.

Cannon GW, Wang BC, Park GS, Koenig A, Collier DH, Keystone EC.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):919-25. Epub 2013 Nov 14.

PMID:
24237999
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk